GEN Exclusives

More »

GEN News Highlights

More »
May 19, 2009

Opsona Receives Commitment for $4.5M in Series B Financing

Opsona Receives Commitment for $4.5M in Series B Financing

Opsona nets $4.5 million in Series B Financing

  • Roche Venture Fund and Enterprise Ireland have committed an additional €3.3 million, or $4.5 million, to the series B financing announced by Opsona Therapeutics this February. This brings the total series B financing to €21.3 million, or $29 million. Previous investors include Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital, and Seroba-Kernel.

    The financing supports the expansion of Opsona's clinical development pipeline, targeting inflammatory and autoimmune disease such as rheumatoid arthritis and lupus.

    "We are delighted by the caliber of investors who have supported our Series B financing," says Mark Heffernan, CEO of Opsona Therapeutics. "The investment by Roche Venture Fund is a further endorsement of Opsona's approach to targeting the innate immune system, and the continued support of Enterprise Ireland demonstrates their commitment to investment in high-potential companies."ADNFCR-2184-ID-19176667-ADNFCR



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?